Keros Therapeutics (KROS)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Keros Therapeutics (KROS)
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Key Insights
Critical company metrics and information
Share Price
$70.00Market Cap
$2.84 BillionTotal Outstanding Shares
40.51 Million SharesTotal Employees
160Dividend
No dividendIPO Date
April 8, 2020SIC Description
Pharmaceutical PreparationsHomepage
https://www.kerostx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $243.03 Million |
Net Cash Flow From Financing Activities | $385.53 Million |
Net Cash Flow From Investing Activities, Continuing | $-2.18 Million |
Net Cash Flow From Operating Activities, Continuing | $-140.32 Million |
Net Cash Flow From Investing Activities | $-2.18 Million |
Net Cash Flow From Financing Activities, Continuing | $385.53 Million |
Net Cash Flow From Operating Activities | $-140.32 Million |
Net Cash Flow | $243.03 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Research and Development | $165.49 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-181.57 Million |
Net Income/Loss | $-181.57 Million |
Diluted Earnings Per Share | $5.22 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Diluted Average Shares | $36.69 Million |
Benefits Costs and Expenses | $153.14 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Nonoperating Income/Loss | $22.46 Million |
Basic Average Shares | $36.69 Million |
Revenues | $651000.00 |
Net Income/Loss Attributable To Parent | $-181.57 Million |
Operating Income/Loss | $-204.03 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Income/Loss From Continuing Operations Before Tax | $-152.49 Million |
Other Operating Expenses | $39.19 Million |
Income/Loss From Continuing Operations After Tax | $-181.57 Million |
Basic Earnings Per Share | $5.22 |
Costs And Expenses | $187.74 Million |
Operating Expenses | $204.69 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Liabilities And Equity | $579.27 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Assets | $579.27 Million |
Wages | $8.03 Million |
Current Assets | $552.05 Million |
Current Liabilities | $29.01 Million |
Noncurrent Liabilities | $17.43 Million |
Noncurrent Assets | $27.23 Million |
Liabilities | $46.44 Million |
Accounts Payable | $4.98 Million |
Equity Attributable To Parent | $532.84 Million |
Other Current Liabilities | $16.00 Million |
Equity | $532.84 Million |
Fixed Assets | $4.37 Million |
Other Non-current Assets | $22.86 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.